First Manhattan’s Ovid Therapeutics OVID Stock Holding History

First Manhattan’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.9K	Hold	26,000	–	–	﹤0.01%	739
2026 Q1	$57.7K	Hold	26,000	–	–	﹤0.01%	749
2025 Q4	$42.4K	Hold	26,000	–	–	﹤0.01%	726
2025 Q3	$33.8K	Hold	26,000	–	–	﹤0.01%	712
2025 Q2	$8.58K	Hold	26,000	–	–	﹤0.01%	698
2025 Q1	$8.11K	Hold	26,000	–	–	﹤0.01%	678
2024 Q4	$24.3K	Hold	26,000	–	–	﹤0.01%	676
2024 Q3	$30.7K	Hold	26,000	–	–	﹤0.01%	677
2024 Q2	$20K	Hold	26,000	–	–	﹤0.01%	663
2024 Q1	$79.3K	Hold	26,000	–	–	﹤0.01%	801
2023 Q4	$83.7K	Hold	26,000	–	–	﹤0.01%	785
2023 Q3	$99.8K	Hold	26,000	–	–	﹤0.01%	764
2023 Q2	$85.3K	Hold	26,000	–	–	﹤0.01%	797
2023 Q1	$67.1K	Hold	26,000	–	–	﹤0.01%	873
2022 Q4	$48.4K	Hold	26,000	–	–	﹤0.01%	951
2022 Q3	$47K	Hold	26,000	–	–	﹤0.01%	941
2022 Q2	$55K	Hold	26,000	–	–	﹤0.01%	956
2022 Q1	$81K	Buy	26,000 +18,000	+225%	+$56.6K	﹤0.01%	920
2021 Q4	$25K	Sell	8,000 -18,000	-69%	-$61.7K	﹤0.01%	1130
2021 Q3	$87K	Hold	26,000	–	–	﹤0.01%	889
2021 Q2	$101K	Buy	26,000 +8,000	+44%	+$31.6K	﹤0.01%	861
2021 Q1	$72K	Hold	18,000	–	–	﹤0.01%	885
2020 Q4	$41K	Hold	18,000	–	–	﹤0.01%	938
2020 Q3	$103K	Hold	18,000	–	–	﹤0.01%	770
2020 Q2	$132K	Hold	18,000	–	–	﹤0.01%	718
2020 Q1	$53K	Hold	18,000	–	–	﹤0.01%	836
2019 Q4	$74K	Hold	18,000	–	–	﹤0.01%	842
2019 Q3	$58K	Buy	+18,000	New	+$40.9K	﹤0.01%	888

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

First Manhattan's OVID Position: Q2 2026 in Review

First Manhattan held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 26,000 shares worth $69.9K. The position accounts for ﹤0.01% of the portfolio, ranked #739.

First Manhattan first reported a position in OVID in Q3 2019 and has held it in 28 quarters since. The position peaked at $132K in Q2 2020. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

First Manhattan held 26,000 shares of Ovid Therapeutics worth $69.9K as of Q2 2026.
First Manhattan left its Ovid Therapeutics share count unchanged in Q2 2026.
Ovid Therapeutics made up ﹤0.01% of First Manhattan's portfolio in Q2 2026, its #739 holding.
First Manhattan first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 28 quarters since.
First Manhattan's Ovid Therapeutics position peaked at $132K in Q2 2020.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.